ObsEva is advancing a pipeline of orally administered, clinical-stage innovative compounds to treat women’s reproductive health conditions.
Oral PGF2α receptor antagonist
EU Phase 2a PROLONG
Interim Efficacy Q4 2019
* Study completed: Week 10 ongoing pregnancy primary endpoint met – Live Birth Rate secondary endpoint met
** Second Phase 3 trial (EU/Canada/Russia): recruitment completed (May2019)
*** Study completed: Primary and secondary endpoints met
We are currently conducting six international clinical research studies.Read more